[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fx8xXE_AT8njj58tOUHIZDDzrmM8VKCkgIaXd_SUnOEA":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":32,"phaseBuckets":63,"rows":70},"LG Chem",[4],68,false,7,8,33625,11,14,[14,17,19,21,23,25,27,29],{"name":15,"count":16},"Gout",10,{"name":18,"count":16},"Hyperuricemia",{"name":20,"count":9},"Poliomyelitis",{"name":22,"count":8},"Diphtheria",{"name":24,"count":8},"Tetanus",{"name":26,"count":8},"Pertussis",{"name":28,"count":8},"Hepatitis B",{"name":30,"count":31},"Healthy",6,[33,38,43,48,53,58],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT06618196","Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of Age","2025-06-30","LR20062",{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT06921395","Phase IV Study to Evaluate the Efficacy and Safety of Fang Le Shu Compared to Guo Na Fen for Controlled Ovarian Stimulation in Infertile Women Undergoing in Vitro Fertilization-embryo Transfer (IVF-ET).","2025-09-30","Fang Le Shu",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT07399470","A Clinical Study in Healthy Adults to See How the Body Processes and How Safe a Tablet That Combines Gemigliptin, Dapagliflozin, and Metformin is, Compared With Taking Zemiglo and Xigduo XR Together While Fasting.","2026-02-28","Test drug: Fixed-dose combination of gemigliptin\u002Fdapagliflozin\u002Fmetformin 50\u002F10\u002F1000 mg",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT07396844","The Food Effect on Pharmacokinetics of Fixed Dose Combination of Gemigliptin\u002FDapagliflozin\u002FMetformin in Healthy Volunteers","2026-07-31","Fixed-dose combination of gemigliptin\u002Fdapagliflozin\u002Fmetformin 50\u002F10\u002F1000 mg",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT06947499","A Phase II\u002FIII Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series","2026-11","LBVD",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT06332755","Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC","2027-11","Phase 1a: LB-LR1109",[64,65,66,67,68,69],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[71,97,115,149,171,205,223,250,268,290,314,332,397,419,437,462,510,528,546,571,596,631,670,696,714,738,756,783,808,843,865,897,923,941,968,986,1009,1033,1058,1076,1100,1124,1149,1173,1191,1209,1227,1245,1263,1289,1307,1325,1350,1368,1394,1412,1437,1455,1482,1500,1518,1542,1560,1583,1610,1632,1656,1680,1706,1724,1742,1769,1794],{"intervention":42,"totalTrials":72,"cells":73},1,{"EARLY_PHASE1":74,"PHASE1":77,"PHASE2":79,"PHASE3":81,"PHASE4":83,"NA":95},{"trials":75,"activeCount":76},[],0,{"trials":78,"activeCount":76},[],{"trials":80,"activeCount":76},[],{"trials":82,"activeCount":76},[],{"trials":84,"activeCount":72,"soonestReadout":41},[85],{"nctId":39,"briefTitle":40,"status":86,"phases":87,"primaryCompletion":41,"completion":88,"start":89,"enrollment":90,"conditions":91,"interventions":93},"RECRUITING",[68],"2026-06-30","2025-02-15",248,[92],"Female Infertility",[42,94],"Guo Na Fen",{"trials":96,"activeCount":76},[],{"intervention":94,"totalTrials":72,"cells":98},{"EARLY_PHASE1":99,"PHASE1":101,"PHASE2":103,"PHASE3":105,"PHASE4":107,"NA":113},{"trials":100,"activeCount":76},[],{"trials":102,"activeCount":76},[],{"trials":104,"activeCount":76},[],{"trials":106,"activeCount":76},[],{"trials":108,"activeCount":72,"soonestReadout":41},[109],{"nctId":39,"briefTitle":40,"status":86,"phases":110,"primaryCompletion":41,"completion":88,"start":89,"enrollment":90,"conditions":111,"interventions":112},[68],[92],[42,94],{"trials":114,"activeCount":76},[],{"intervention":57,"totalTrials":116,"cells":117},2,{"EARLY_PHASE1":118,"PHASE1":120,"PHASE2":122,"PHASE3":124,"PHASE4":145,"NA":147},{"trials":119,"activeCount":76},[],{"trials":121,"activeCount":76},[],{"trials":123,"activeCount":76},[],{"trials":125,"activeCount":72,"soonestReadout":56},[126,137],{"nctId":127,"briefTitle":128,"status":129,"phases":130,"primaryCompletion":41,"completion":41,"start":131,"enrollment":132,"conditions":133,"interventions":135},"NCT05457946","Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary Series","UNKNOWN",[66,67],"2023-04-01",1438,[22,24,26,28,20,134],"Haemophilus Influenzae Type B Infection",[57,136],"Pentavalent vaccine and Inactivated Polio vaccine",{"nctId":54,"briefTitle":55,"status":86,"phases":138,"primaryCompletion":56,"completion":139,"start":140,"enrollment":141,"conditions":142,"interventions":144},[66,67],"2027-04","2025-05-30",1186,[22,24,26,28,20,143],"Haemophilus Influenzae Type b",[57,136],{"trials":146,"activeCount":76},[],{"trials":148,"activeCount":76},[],{"intervention":136,"totalTrials":116,"cells":150},{"EARLY_PHASE1":151,"PHASE1":153,"PHASE2":155,"PHASE3":157,"PHASE4":167,"NA":169},{"trials":152,"activeCount":76},[],{"trials":154,"activeCount":76},[],{"trials":156,"activeCount":76},[],{"trials":158,"activeCount":72,"soonestReadout":56},[159,163],{"nctId":127,"briefTitle":128,"status":129,"phases":160,"primaryCompletion":41,"completion":41,"start":131,"enrollment":132,"conditions":161,"interventions":162},[66,67],[22,24,26,28,20,134],[57,136],{"nctId":54,"briefTitle":55,"status":86,"phases":164,"primaryCompletion":56,"completion":139,"start":140,"enrollment":141,"conditions":165,"interventions":166},[66,67],[22,24,26,28,20,143],[57,136],{"trials":168,"activeCount":76},[],{"trials":170,"activeCount":76},[],{"intervention":172,"totalTrials":116,"cells":173},"DTaP-HepB-IPV-Hib vaccine",{"EARLY_PHASE1":174,"PHASE1":176,"PHASE2":189,"PHASE3":199,"PHASE4":201,"NA":203},{"trials":175,"activeCount":76},[],{"trials":177,"activeCount":76},[178],{"nctId":179,"briefTitle":180,"status":129,"phases":181,"primaryCompletion":182,"completion":183,"start":184,"enrollment":185,"conditions":186,"interventions":188},"NCT05952596","A Study to Evaluate Safety and Immunogenicity of APV006 in Healthy Adults",[65],"2023-10-31","2024-03-31","2023-07-17",42,[22,24,26,20,28,187],"Haemophilus Influenzae Type b Infection",[172,172],{"trials":190,"activeCount":72,"soonestReadout":36},[191],{"nctId":34,"briefTitle":35,"status":192,"phases":193,"primaryCompletion":36,"completion":194,"start":195,"enrollment":196,"conditions":197,"interventions":198},"NOT_YET_RECRUITING",[66],"2026-04-30","2024-10-02",336,[22,24,26,28,20,134],[37,172],{"trials":200,"activeCount":76},[],{"trials":202,"activeCount":76},[],{"trials":204,"activeCount":76},[],{"intervention":37,"totalTrials":72,"cells":206},{"EARLY_PHASE1":207,"PHASE1":209,"PHASE2":211,"PHASE3":217,"PHASE4":219,"NA":221},{"trials":208,"activeCount":76},[],{"trials":210,"activeCount":76},[],{"trials":212,"activeCount":72,"soonestReadout":36},[213],{"nctId":34,"briefTitle":35,"status":192,"phases":214,"primaryCompletion":36,"completion":194,"start":195,"enrollment":196,"conditions":215,"interventions":216},[66],[22,24,26,28,20,134],[37,172],{"trials":218,"activeCount":76},[],{"trials":220,"activeCount":76},[],{"trials":222,"activeCount":76},[],{"intervention":62,"totalTrials":72,"cells":224},{"EARLY_PHASE1":225,"PHASE1":227,"PHASE2":242,"PHASE3":244,"PHASE4":246,"NA":248},{"trials":226,"activeCount":76},[],{"trials":228,"activeCount":72,"soonestReadout":61},[229],{"nctId":59,"briefTitle":60,"status":86,"phases":230,"primaryCompletion":61,"completion":231,"start":232,"enrollment":233,"conditions":234,"interventions":240},[65],"2028-03","2024-06-05",76,[235,236,237,238,239],"Non-small Cell Lung Cancer(NSCLC)","Head and Neck Squamous Cell Carcinoma(HNSCC)","Renal Cell Carcinoma(RCC)","Urothelial Carcinoma","Malignant Melanoma",[62,241],"Phase 1b: LB-LR1109 and Atezolizumab",{"trials":243,"activeCount":76},[],{"trials":245,"activeCount":76},[],{"trials":247,"activeCount":76},[],{"trials":249,"activeCount":76},[],{"intervention":241,"totalTrials":72,"cells":251},{"EARLY_PHASE1":252,"PHASE1":254,"PHASE2":260,"PHASE3":262,"PHASE4":264,"NA":266},{"trials":253,"activeCount":76},[],{"trials":255,"activeCount":72,"soonestReadout":61},[256],{"nctId":59,"briefTitle":60,"status":86,"phases":257,"primaryCompletion":61,"completion":231,"start":232,"enrollment":233,"conditions":258,"interventions":259},[65],[235,236,237,238,239],[62,241],{"trials":261,"activeCount":76},[],{"trials":263,"activeCount":76},[],{"trials":265,"activeCount":76},[],{"trials":267,"activeCount":76},[],{"intervention":52,"totalTrials":72,"cells":269},{"EARLY_PHASE1":270,"PHASE1":272,"PHASE2":282,"PHASE3":284,"PHASE4":286,"NA":288},{"trials":271,"activeCount":76},[],{"trials":273,"activeCount":72,"soonestReadout":51},[274],{"nctId":49,"briefTitle":50,"status":192,"phases":275,"primaryCompletion":51,"completion":51,"start":276,"enrollment":277,"conditions":278,"interventions":281},[65],"2026-07-01",28,[30,279,280],"Fasting","Fed",[52],{"trials":283,"activeCount":76},[],{"trials":285,"activeCount":76},[],{"trials":287,"activeCount":76},[],{"trials":289,"activeCount":76},[],{"intervention":47,"totalTrials":72,"cells":291},{"EARLY_PHASE1":292,"PHASE1":294,"PHASE2":306,"PHASE3":308,"PHASE4":310,"NA":312},{"trials":293,"activeCount":76},[],{"trials":295,"activeCount":72,"soonestReadout":46},[296],{"nctId":44,"briefTitle":45,"status":297,"phases":298,"primaryCompletion":46,"completion":46,"start":299,"enrollment":300,"conditions":301,"interventions":304},"ACTIVE_NOT_RECRUITING",[65],"2026-01-09",58,[302,303],"Healthy Volunteers","Fasting Conditions",[47,305],"Reference drug: Gemigliptin (Zemiglo) 50mg, Dapagliflozin\u002Fmetformin (Xigduo XR) 10\u002F1000 mg",{"trials":307,"activeCount":76},[],{"trials":309,"activeCount":76},[],{"trials":311,"activeCount":76},[],{"trials":313,"activeCount":76},[],{"intervention":305,"totalTrials":72,"cells":315},{"EARLY_PHASE1":316,"PHASE1":318,"PHASE2":324,"PHASE3":326,"PHASE4":328,"NA":330},{"trials":317,"activeCount":76},[],{"trials":319,"activeCount":72,"soonestReadout":46},[320],{"nctId":44,"briefTitle":45,"status":297,"phases":321,"primaryCompletion":46,"completion":46,"start":299,"enrollment":300,"conditions":322,"interventions":323},[65],[302,303],[47,305],{"trials":325,"activeCount":76},[],{"trials":327,"activeCount":76},[],{"trials":329,"activeCount":76},[],{"trials":331,"activeCount":76},[],{"intervention":333,"totalTrials":334,"cells":335},"Gemigliptin 50mg",4,{"EARLY_PHASE1":336,"PHASE1":338,"PHASE2":355,"PHASE3":357,"PHASE4":382,"NA":395},{"trials":337,"activeCount":76},[],{"trials":339,"activeCount":76},[340],{"nctId":341,"briefTitle":342,"status":343,"phases":344,"primaryCompletion":345,"completion":346,"start":347,"enrollment":348,"conditions":349,"interventions":351},"NCT03864432","An Ascending Dose, Single\u002FMultiple Dosing, Food Effect Clinical Trial to Evaluate Pharmacokinetics, Safety and Tolerability in Healthy Subjects After Oral Administration of Gemigliptin (Phase I)","COMPLETED",[65],"2019-10-03","2020-02-28","2019-07-02",48,[350],"Type 2 Diabetes Mellitus",[352,333,353,354],"Gemigliptin 25mg","Gemigliptin 100mg","Gemiglptin 50mg multiple dose",{"trials":356,"activeCount":76},[],{"trials":358,"activeCount":76},[359,371],{"nctId":360,"briefTitle":361,"status":343,"phases":362,"primaryCompletion":363,"completion":364,"start":365,"enrollment":366,"conditions":367,"interventions":369},"NCT03842267","A Study to Evaluate the Efficacy and Safety of Gemigliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Dapagliflozin and Metformin (SOLUTION Study)",[67],"2021-05-20","2022-11-30","2019-05-13",315,[368],"Diabetes Mellitus, Type 2",[333,370],"Gemigliptin Placebo",{"nctId":372,"briefTitle":373,"status":129,"phases":374,"primaryCompletion":375,"completion":376,"start":377,"enrollment":378,"conditions":379,"interventions":380},"NCT04255238","A Study to Evaluate the Efficacy and Safety of Dual add-on Therapy With Gemigliptin 50 mg and Dapagliflozin 10 mg Added to Metformin Who Have Inadequate Glycemic Control on Metformin Alone",[67],"2022-05-30","2022-12-30","2020-06-30",468,[368],[333,381],"Dapagliflozin 10mg",{"trials":383,"activeCount":76},[384],{"nctId":385,"briefTitle":386,"status":343,"phases":387,"primaryCompletion":388,"completion":389,"start":390,"enrollment":391,"conditions":392,"interventions":393},"NCT03202563","Trial to Evaluate the Efficacy on Glycemic Variability and Safety of Gemigliptin Compared With Dapagliflozin Added on Metformin Alone or Diabetes Medication Naïve Patient in Type 2 Diabetes Mellitus (Stable II Study)",[68],"2018-07-13","2018-12-07","2017-08-09",71,[350],[333,381,394],"Metformin",{"trials":396,"activeCount":76},[],{"intervention":381,"totalTrials":116,"cells":398},{"EARLY_PHASE1":399,"PHASE1":401,"PHASE2":403,"PHASE3":405,"PHASE4":411,"NA":417},{"trials":400,"activeCount":76},[],{"trials":402,"activeCount":76},[],{"trials":404,"activeCount":76},[],{"trials":406,"activeCount":76},[407],{"nctId":372,"briefTitle":373,"status":129,"phases":408,"primaryCompletion":375,"completion":376,"start":377,"enrollment":378,"conditions":409,"interventions":410},[67],[368],[333,381],{"trials":412,"activeCount":76},[413],{"nctId":385,"briefTitle":386,"status":343,"phases":414,"primaryCompletion":388,"completion":389,"start":390,"enrollment":391,"conditions":415,"interventions":416},[68],[350],[333,381,394],{"trials":418,"activeCount":76},[],{"intervention":394,"totalTrials":72,"cells":420},{"EARLY_PHASE1":421,"PHASE1":423,"PHASE2":425,"PHASE3":427,"PHASE4":429,"NA":435},{"trials":422,"activeCount":76},[],{"trials":424,"activeCount":76},[],{"trials":426,"activeCount":76},[],{"trials":428,"activeCount":76},[],{"trials":430,"activeCount":76},[431],{"nctId":385,"briefTitle":386,"status":343,"phases":432,"primaryCompletion":388,"completion":389,"start":390,"enrollment":391,"conditions":433,"interventions":434},[68],[350],[333,381,394],{"trials":436,"activeCount":76},[],{"intervention":438,"totalTrials":72,"cells":439},"Eupenta Inj.",{"EARLY_PHASE1":440,"PHASE1":442,"PHASE2":444,"PHASE3":446,"PHASE4":448,"NA":460},{"trials":441,"activeCount":76},[],{"trials":443,"activeCount":76},[],{"trials":445,"activeCount":76},[],{"trials":447,"activeCount":76},[],{"trials":449,"activeCount":76},[450],{"nctId":451,"briefTitle":452,"status":129,"phases":453,"primaryCompletion":454,"completion":455,"start":456,"enrollment":457,"conditions":458,"interventions":459},"NCT04056728","A Phase IV Study to Assess the Safety of EupentaTM Inj",[68],"2020-10-12","2020-12-31","2019-09-23",3000,[28,22,134,24,26],[438],{"trials":461,"activeCount":76},[],{"intervention":463,"totalTrials":464,"cells":465},"Tigulixostat",3,{"EARLY_PHASE1":466,"PHASE1":468,"PHASE2":480,"PHASE3":482,"PHASE4":506,"NA":508},{"trials":467,"activeCount":76},[],{"trials":469,"activeCount":76},[470],{"nctId":471,"briefTitle":472,"status":343,"phases":473,"primaryCompletion":474,"completion":475,"start":182,"enrollment":476,"conditions":477,"interventions":478},"NCT06189404","Effect of Tigulixostat on the Pharmacokinetics of Theophylline",[65],"2023-11-13","2023-11-30",24,[15,18],[463,479],"Theophylline",{"trials":481,"activeCount":76},[],{"trials":483,"activeCount":76},[484,496],{"nctId":485,"briefTitle":486,"status":343,"phases":487,"primaryCompletion":488,"completion":488,"start":489,"enrollment":490,"conditions":491,"interventions":494},"NCT05586971","Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients",[67],"2025-05-06","2023-03-30",2202,[15,18,492,493],"Gout Flare","Tophi",[463,495],"Allopurinol",{"nctId":497,"briefTitle":498,"status":343,"phases":499,"primaryCompletion":500,"completion":501,"start":502,"enrollment":503,"conditions":504,"interventions":505},"NCT05586958","Tigulixostat, Phase 3 Study, Placebo Controlled in Gout Patients",[67],"2024-11-04","2024-12-16","2022-10-25",354,[15,18,492,493],[463],{"trials":507,"activeCount":76},[],{"trials":509,"activeCount":76},[],{"intervention":495,"totalTrials":72,"cells":511},{"EARLY_PHASE1":512,"PHASE1":514,"PHASE2":516,"PHASE3":518,"PHASE4":524,"NA":526},{"trials":513,"activeCount":76},[],{"trials":515,"activeCount":76},[],{"trials":517,"activeCount":76},[],{"trials":519,"activeCount":76},[520],{"nctId":485,"briefTitle":486,"status":343,"phases":521,"primaryCompletion":488,"completion":488,"start":489,"enrollment":490,"conditions":522,"interventions":523},[67],[15,18,492,493],[463,495],{"trials":525,"activeCount":76},[],{"trials":527,"activeCount":76},[],{"intervention":370,"totalTrials":72,"cells":529},{"EARLY_PHASE1":530,"PHASE1":532,"PHASE2":534,"PHASE3":536,"PHASE4":542,"NA":544},{"trials":531,"activeCount":76},[],{"trials":533,"activeCount":76},[],{"trials":535,"activeCount":76},[],{"trials":537,"activeCount":76},[538],{"nctId":360,"briefTitle":361,"status":343,"phases":539,"primaryCompletion":363,"completion":364,"start":365,"enrollment":366,"conditions":540,"interventions":541},[67],[368],[333,370],{"trials":543,"activeCount":76},[],{"trials":545,"activeCount":76},[],{"intervention":547,"totalTrials":72,"cells":548},"Inactivated Poliomyelitis Vaccine",{"EARLY_PHASE1":549,"PHASE1":551,"PHASE2":553,"PHASE3":555,"PHASE4":567,"NA":569},{"trials":550,"activeCount":76},[],{"trials":552,"activeCount":76},[],{"trials":554,"activeCount":76},[],{"trials":556,"activeCount":76},[557],{"nctId":558,"briefTitle":559,"status":343,"phases":560,"primaryCompletion":561,"completion":562,"start":563,"enrollment":564,"conditions":565,"interventions":566},"NCT03169725","A Clinical Study to Evaluate the Safety and Immunogenicity of Inactivated Poliomyelitis Vaccine in Healthy Infants",[66,67],"2019-01-18","2019-06-14","2017-05-31",1417,[20],[547,547],{"trials":568,"activeCount":76},[],{"trials":570,"activeCount":76},[],{"intervention":572,"totalTrials":72,"cells":573},"Eupolio",{"EARLY_PHASE1":574,"PHASE1":576,"PHASE2":578,"PHASE3":580,"PHASE4":592,"NA":594},{"trials":575,"activeCount":76},[],{"trials":577,"activeCount":76},[],{"trials":579,"activeCount":76},[],{"trials":581,"activeCount":76},[582],{"nctId":583,"briefTitle":584,"status":343,"phases":585,"primaryCompletion":586,"completion":586,"start":587,"enrollment":588,"conditions":589,"interventions":591},"NCT05431933","Study to Evaluate Eupolio(IPV)'s Safety, Long-term Protective Effect and Boosting Effect of One Booster Dose in the Three Primary Vaccination Plus Boosting Schedule, and Protective Effect in the Schedule With Bivalent OPV in Infants",[67],"2024-11-06","2023-01-10",2001,[20,590],"Vaccine Reaction",[572],{"trials":593,"activeCount":76},[],{"trials":595,"activeCount":76},[],{"intervention":597,"totalTrials":116,"cells":598},"LC51-0255",{"EARLY_PHASE1":599,"PHASE1":601,"PHASE2":612,"PHASE3":625,"PHASE4":627,"NA":629},{"trials":600,"activeCount":76},[],{"trials":602,"activeCount":76},[603],{"nctId":604,"briefTitle":605,"status":343,"phases":606,"primaryCompletion":607,"completion":608,"start":563,"enrollment":609,"conditions":610,"interventions":611},"NCT03174613","A Study To Evaluate The Safety, Pharmacokinetics\u002FPharmacodynamics (PK\u002FPD) and Food Effect Of LC51-0255",[65],"2019-06-12","2019-07-11",100,[30],[597],{"trials":613,"activeCount":76},[614],{"nctId":615,"briefTitle":616,"status":617,"phases":618,"primaryCompletion":619,"completion":620,"start":621,"enrollment":76,"conditions":622,"interventions":624},"NCT04096573","Efficacy and Safety of LC51-0255 in Subjects With Ulcerative Colitis","WITHDRAWN",[66],"2021-11","2022-08","2020-04",[623],"Ulcerative Colitis",[597],{"trials":626,"activeCount":76},[],{"trials":628,"activeCount":76},[],{"trials":630,"activeCount":76},[],{"intervention":632,"totalTrials":116,"cells":633},"Prevnar13",{"EARLY_PHASE1":634,"PHASE1":636,"PHASE2":651,"PHASE3":664,"PHASE4":666,"NA":668},{"trials":635,"activeCount":76},[],{"trials":637,"activeCount":76},[638],{"nctId":639,"briefTitle":640,"status":129,"phases":641,"primaryCompletion":642,"completion":643,"start":644,"enrollment":645,"conditions":646,"interventions":648},"NCT03549208","A Study to Evaluate the Safety and Immunogeneicity of Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults",[65],"2019-04-01","2019-07-25","2018-07-01",60,[647],"Pneumococcal Infection",[649,650,632],"LBVE01","LBVE02",{"trials":652,"activeCount":76},[653],{"nctId":654,"briefTitle":655,"status":343,"phases":656,"primaryCompletion":657,"completion":658,"start":659,"enrollment":660,"conditions":661,"interventions":662},"NCT03467984","A Study to Evaluate the Safety and Immunogenecity of LBVE(Multivalent Pneumococcal Conjugate Vaccine) in Healthy Infants",[66],"2018-10-05","2019-03-27","2018-05-25",230,[647],[663,632],"LBVE",{"trials":665,"activeCount":76},[],{"trials":667,"activeCount":76},[],{"trials":669,"activeCount":76},[],{"intervention":671,"totalTrials":72,"cells":672},"LG00034053",{"EARLY_PHASE1":673,"PHASE1":675,"PHASE2":677,"PHASE3":690,"PHASE4":692,"NA":694},{"trials":674,"activeCount":76},[],{"trials":676,"activeCount":76},[],{"trials":678,"activeCount":76},[679],{"nctId":680,"briefTitle":681,"status":343,"phases":682,"primaryCompletion":683,"completion":684,"start":685,"enrollment":686,"conditions":687,"interventions":689},"NCT05237752","A Phase Ib\u002FII Clinical Trial to Evaluate the Safety and Efficacy of LG00034053 in Patients With Knee OA",[65,66],"2023-12-19","2024-03-11","2022-04-27",74,[688],"Osteoarthritis, Knee",[671],{"trials":691,"activeCount":76},[],{"trials":693,"activeCount":76},[],{"trials":695,"activeCount":76},[],{"intervention":663,"totalTrials":72,"cells":697},{"EARLY_PHASE1":698,"PHASE1":700,"PHASE2":702,"PHASE3":708,"PHASE4":710,"NA":712},{"trials":699,"activeCount":76},[],{"trials":701,"activeCount":76},[],{"trials":703,"activeCount":76},[704],{"nctId":654,"briefTitle":655,"status":343,"phases":705,"primaryCompletion":657,"completion":658,"start":659,"enrollment":660,"conditions":706,"interventions":707},[66],[647],[663,632],{"trials":709,"activeCount":76},[],{"trials":711,"activeCount":76},[],{"trials":713,"activeCount":76},[],{"intervention":715,"totalTrials":72,"cells":716},"DTwP-HepB-Sabin IPV-Hib",{"EARLY_PHASE1":717,"PHASE1":719,"PHASE2":721,"PHASE3":732,"PHASE4":734,"NA":736},{"trials":718,"activeCount":76},[],{"trials":720,"activeCount":76},[],{"trials":722,"activeCount":76},[723],{"nctId":724,"briefTitle":725,"status":129,"phases":726,"primaryCompletion":621,"completion":727,"start":728,"enrollment":196,"conditions":729,"interventions":730},"NCT04073459","Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy Infants",[66],"2020-08","2019-11",[22,24,26,28,20,187],[715,731],"Pentavalent vaccine and Salk IPV",{"trials":733,"activeCount":76},[],{"trials":735,"activeCount":76},[],{"trials":737,"activeCount":76},[],{"intervention":731,"totalTrials":72,"cells":739},{"EARLY_PHASE1":740,"PHASE1":742,"PHASE2":744,"PHASE3":750,"PHASE4":752,"NA":754},{"trials":741,"activeCount":76},[],{"trials":743,"activeCount":76},[],{"trials":745,"activeCount":76},[746],{"nctId":724,"briefTitle":725,"status":129,"phases":747,"primaryCompletion":621,"completion":727,"start":728,"enrollment":196,"conditions":748,"interventions":749},[66],[22,24,26,28,20,187],[715,731],{"trials":751,"activeCount":76},[],{"trials":753,"activeCount":76},[],{"trials":755,"activeCount":76},[],{"intervention":757,"totalTrials":72,"cells":758},"LB54640",{"EARLY_PHASE1":759,"PHASE1":761,"PHASE2":763,"PHASE3":777,"PHASE4":779,"NA":781},{"trials":760,"activeCount":76},[],{"trials":762,"activeCount":76},[],{"trials":764,"activeCount":76},[765],{"nctId":766,"briefTitle":767,"status":129,"phases":768,"primaryCompletion":769,"completion":770,"start":771,"enrollment":334,"conditions":772,"interventions":776},"NCT06041841","A Phase 2 Study to Assess Efficacy and Safety of LB54640 in Patients With Genetic Obesity",[66],"2024-12","2025-12","2023-12",[773,774,775],"POMC Deficiency Obesity","PCSK1 Deficiency Obesity","LEPR Deficiency Obesity",[757],{"trials":778,"activeCount":76},[],{"trials":780,"activeCount":76},[],{"trials":782,"activeCount":76},[],{"intervention":784,"totalTrials":72,"cells":785},"LC350189 formulated",{"EARLY_PHASE1":786,"PHASE1":788,"PHASE2":790,"PHASE3":802,"PHASE4":804,"NA":806},{"trials":787,"activeCount":76},[],{"trials":789,"activeCount":76},[],{"trials":791,"activeCount":76},[792],{"nctId":793,"briefTitle":794,"status":343,"phases":795,"primaryCompletion":796,"completion":797,"start":798,"enrollment":799,"conditions":800,"interventions":801},"NCT03934099","A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia",[66],"2021-05-03","2021-05-17","2019-12-02",156,[15,18],[784],{"trials":803,"activeCount":76},[],{"trials":805,"activeCount":76},[],{"trials":807,"activeCount":76},[],{"intervention":809,"totalTrials":116,"cells":810},"Gemigliptin tartrate sesquihydrate and metformin",{"EARLY_PHASE1":811,"PHASE1":813,"PHASE2":835,"PHASE3":837,"PHASE4":839,"NA":841},{"trials":812,"activeCount":76},[],{"trials":814,"activeCount":76},[815,826],{"nctId":816,"briefTitle":817,"status":343,"phases":818,"primaryCompletion":819,"completion":819,"start":820,"enrollment":821,"conditions":822,"interventions":824},"NCT04317703","Bioequivalence Study for Fixed Dose Combination Zemimet® SR Tab. 50\u002F1000 and Coadministration of Gemigliptin 50 mg and Metformin 1000 mg.",[65],"2020-09-05","2020-08-19",40,[823],"Type 2 Diabetes",[809,825],"gemigliptin 50 mg and metformin hydrochloride 1000 mg prolonged release",{"nctId":827,"briefTitle":828,"status":129,"phases":829,"primaryCompletion":830,"completion":830,"start":831,"enrollment":476,"conditions":832,"interventions":834},"NCT04050098","Bioequivalence Study for Gemigliptin\u002FMetformin 50\u002F1000 mg and Coadministration of Gemigliptin 50 mg and Metformin 1000 mg.",[65],"2019-11-30","2019-11-01",[833],"Type2 Diabetes",[825,809],{"trials":836,"activeCount":76},[],{"trials":838,"activeCount":76},[],{"trials":840,"activeCount":76},[],{"trials":842,"activeCount":76},[],{"intervention":825,"totalTrials":116,"cells":844},{"EARLY_PHASE1":845,"PHASE1":847,"PHASE2":857,"PHASE3":859,"PHASE4":861,"NA":863},{"trials":846,"activeCount":76},[],{"trials":848,"activeCount":76},[849,853],{"nctId":816,"briefTitle":817,"status":343,"phases":850,"primaryCompletion":819,"completion":819,"start":820,"enrollment":821,"conditions":851,"interventions":852},[65],[823],[809,825],{"nctId":827,"briefTitle":828,"status":129,"phases":854,"primaryCompletion":830,"completion":830,"start":831,"enrollment":476,"conditions":855,"interventions":856},[65],[833],[825,809],{"trials":858,"activeCount":76},[],{"trials":860,"activeCount":76},[],{"trials":862,"activeCount":76},[],{"trials":864,"activeCount":76},[],{"intervention":866,"totalTrials":116,"cells":867},"Xanthine Oxidase Inhibitor",{"EARLY_PHASE1":868,"PHASE1":870,"PHASE2":889,"PHASE3":891,"PHASE4":893,"NA":895},{"trials":869,"activeCount":76},[],{"trials":871,"activeCount":76},[872,881],{"nctId":873,"briefTitle":874,"status":343,"phases":875,"primaryCompletion":876,"completion":876,"start":877,"enrollment":476,"conditions":878,"interventions":879},"NCT04139824","The Effect of Naproxen on the Pharmacokinetic Profile of LC350189 in Healthy Adults",[65],"2020-02-25","2020-01-22",[15,18],[866,880],"nonsteroidal anti-inflammatory drug",{"nctId":882,"briefTitle":883,"status":343,"phases":884,"primaryCompletion":885,"completion":885,"start":886,"enrollment":476,"conditions":887,"interventions":888},"NCT03927677","The Effect of Colchicine on the Pharmacokinetic Profile of LC350189 in Healthy Aldults.",[65],"2019-11-26","2019-11-05",[15,18],[866],{"trials":890,"activeCount":76},[],{"trials":892,"activeCount":76},[],{"trials":894,"activeCount":76},[],{"trials":896,"activeCount":76},[],{"intervention":898,"totalTrials":72,"cells":899},"Combination of gemigliptin\u002Fmetformin HCl sustained release 50\u002F1000mg",{"EARLY_PHASE1":900,"PHASE1":902,"PHASE2":915,"PHASE3":917,"PHASE4":919,"NA":921},{"trials":901,"activeCount":76},[],{"trials":903,"activeCount":76},[904],{"nctId":905,"briefTitle":906,"status":343,"phases":907,"primaryCompletion":908,"completion":908,"start":909,"enrollment":910,"conditions":911,"interventions":913},"NCT03355014","BE Study of the Combinations of Gemigliptin\u002FMetformin HCl Extended Release 50\u002F1000mg(25\u002F500mg x 2 Tablets) in Comparison to Each Component Administered Alone",[65],"2018-01-12","2017-12-13",70,[912],"Healthy Male Volunteers",[898,914],"Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg",{"trials":916,"activeCount":76},[],{"trials":918,"activeCount":76},[],{"trials":920,"activeCount":76},[],{"trials":922,"activeCount":76},[],{"intervention":914,"totalTrials":72,"cells":924},{"EARLY_PHASE1":925,"PHASE1":927,"PHASE2":933,"PHASE3":935,"PHASE4":937,"NA":939},{"trials":926,"activeCount":76},[],{"trials":928,"activeCount":76},[929],{"nctId":905,"briefTitle":906,"status":343,"phases":930,"primaryCompletion":908,"completion":908,"start":909,"enrollment":910,"conditions":931,"interventions":932},[65],[912],[898,914],{"trials":934,"activeCount":76},[],{"trials":936,"activeCount":76},[],{"trials":938,"activeCount":76},[],{"trials":940,"activeCount":76},[],{"intervention":942,"totalTrials":72,"cells":943},"Test drug: Fixed-dose combination (FDC) of gemigliptin\u002Fdapagliflozin\u002Fmetformin 50\u002F10\u002F1000 mg",{"EARLY_PHASE1":944,"PHASE1":946,"PHASE2":960,"PHASE3":962,"PHASE4":964,"NA":966},{"trials":945,"activeCount":76},[],{"trials":947,"activeCount":76},[948],{"nctId":949,"briefTitle":950,"status":343,"phases":951,"primaryCompletion":952,"completion":952,"start":953,"enrollment":954,"conditions":955,"interventions":958},"NCT07333742","A Clinical Study to See How the Body Handles and How Safe a Combination Tablet of Gemigliptin, Dapagliflozin, and Metformin 50\u002F10\u002F1000mg is Compared to Taking Gemigliptin 50mg Separately With Dapagliflozin\u002FMetformin 10\u002F1000mg in Healthy Adults After a Meal",[65],"2025-11-27","2025-09-29",50,[956,957],"Fed Conditions","Healthy Volunteer",[942,959],"Reference drug: gemigliptin (Zemiglo) 50mg, Xigduo XR 10\u002F1000 mg",{"trials":961,"activeCount":76},[],{"trials":963,"activeCount":76},[],{"trials":965,"activeCount":76},[],{"trials":967,"activeCount":76},[],{"intervention":959,"totalTrials":72,"cells":969},{"EARLY_PHASE1":970,"PHASE1":972,"PHASE2":978,"PHASE3":980,"PHASE4":982,"NA":984},{"trials":971,"activeCount":76},[],{"trials":973,"activeCount":76},[974],{"nctId":949,"briefTitle":950,"status":343,"phases":975,"primaryCompletion":952,"completion":952,"start":953,"enrollment":954,"conditions":976,"interventions":977},[65],[956,957],[942,959],{"trials":979,"activeCount":76},[],{"trials":981,"activeCount":76},[],{"trials":983,"activeCount":76},[],{"trials":985,"activeCount":76},[],{"intervention":987,"totalTrials":72,"cells":988},"LC542019",{"EARLY_PHASE1":989,"PHASE1":991,"PHASE2":1001,"PHASE3":1003,"PHASE4":1005,"NA":1007},{"trials":990,"activeCount":76},[],{"trials":992,"activeCount":76},[993],{"nctId":994,"briefTitle":995,"status":343,"phases":996,"primaryCompletion":997,"completion":997,"start":998,"enrollment":609,"conditions":999,"interventions":1000},"NCT06333977","A Study of LC542019 in Healthy Subjects and Subjects With T2DM",[65],"2023-12-14","2022-03-25",[30,368],[987],{"trials":1002,"activeCount":76},[],{"trials":1004,"activeCount":76},[],{"trials":1006,"activeCount":76},[],{"trials":1008,"activeCount":76},[],{"intervention":1010,"totalTrials":72,"cells":1011},"Somatropin",{"EARLY_PHASE1":1012,"PHASE1":1014,"PHASE2":1025,"PHASE3":1027,"PHASE4":1029,"NA":1031},{"trials":1013,"activeCount":76},[],{"trials":1015,"activeCount":76},[1016],{"nctId":1017,"briefTitle":1018,"status":343,"phases":1019,"primaryCompletion":1020,"completion":1020,"start":1021,"enrollment":476,"conditions":1022,"interventions":1024},"NCT04085224","6x3 Crossover, Bioavailability, Safety and Tolerability Among Different Eutropin Formulations in Healthy Volunteers",[65],"2020-01-02","2019-09-10",[1023],"Bioavailability, Safety and Tolerability Among Different Eutropin Formulations in Healthy Volunteers",[1010],{"trials":1026,"activeCount":76},[],{"trials":1028,"activeCount":76},[],{"trials":1030,"activeCount":76},[],{"trials":1032,"activeCount":76},[],{"intervention":1034,"totalTrials":72,"cells":1035},"Film-coated",{"EARLY_PHASE1":1036,"PHASE1":1038,"PHASE2":1050,"PHASE3":1052,"PHASE4":1054,"NA":1056},{"trials":1037,"activeCount":76},[],{"trials":1039,"activeCount":76},[1040],{"nctId":1041,"briefTitle":1042,"status":343,"phases":1043,"primaryCompletion":1044,"completion":1045,"start":1046,"enrollment":1047,"conditions":1048,"interventions":1049},"NCT04360343","Compare the Pharmacokinetics, Pharmacodynamics and Safety\u002FTolerability of LC51-0255 Film-coated Tablet (SG85) With LC51-0255 Uncoated Tablet (SG82) in Healthy Subjects",[65],"2020-10-01","2020-12-01","2020-07-01",18,[623],[1034],{"trials":1051,"activeCount":76},[],{"trials":1053,"activeCount":76},[],{"trials":1055,"activeCount":76},[],{"trials":1057,"activeCount":76},[],{"intervention":479,"totalTrials":72,"cells":1059},{"EARLY_PHASE1":1060,"PHASE1":1062,"PHASE2":1068,"PHASE3":1070,"PHASE4":1072,"NA":1074},{"trials":1061,"activeCount":76},[],{"trials":1063,"activeCount":76},[1064],{"nctId":471,"briefTitle":472,"status":343,"phases":1065,"primaryCompletion":474,"completion":475,"start":182,"enrollment":476,"conditions":1066,"interventions":1067},[65],[15,18],[463,479],{"trials":1069,"activeCount":76},[],{"trials":1071,"activeCount":76},[],{"trials":1073,"activeCount":76},[],{"trials":1075,"activeCount":76},[],{"intervention":1077,"totalTrials":72,"cells":1078},"TT-01025-CL",{"EARLY_PHASE1":1079,"PHASE1":1081,"PHASE2":1092,"PHASE3":1094,"PHASE4":1096,"NA":1098},{"trials":1080,"activeCount":76},[],{"trials":1082,"activeCount":76},[1083],{"nctId":1084,"briefTitle":1085,"status":129,"phases":1086,"primaryCompletion":1087,"completion":1087,"start":1088,"enrollment":1089,"conditions":1090,"interventions":1091},"NCT04730050","A Phase I Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetic Characteristics of TT-01025-CL in Healthy Subjects",[65],"2021-12","2021-02-17",64,[30],[1077],{"trials":1093,"activeCount":76},[],{"trials":1095,"activeCount":76},[],{"trials":1097,"activeCount":76},[],{"trials":1099,"activeCount":76},[],{"intervention":1101,"totalTrials":72,"cells":1102},"Eutropin 4IU, Eutropin AQ 12IU, Eutropin Pen 36IU",{"EARLY_PHASE1":1103,"PHASE1":1105,"PHASE2":1116,"PHASE3":1118,"PHASE4":1120,"NA":1122},{"trials":1104,"activeCount":76},[],{"trials":1106,"activeCount":76},[1107],{"nctId":1108,"briefTitle":1109,"status":129,"phases":1110,"primaryCompletion":1111,"completion":1112,"start":563,"enrollment":476,"conditions":1113,"interventions":1115},"NCT03154840","Relative Bioavailability Among Different Eutropin Formulations",[65],"2017-07-10","2017-11-30",[1114],"Relative Bioavailability",[1101],{"trials":1117,"activeCount":76},[],{"trials":1119,"activeCount":76},[],{"trials":1121,"activeCount":76},[],{"trials":1123,"activeCount":76},[],{"intervention":1125,"totalTrials":72,"cells":1126},"LC350189",{"EARLY_PHASE1":1127,"PHASE1":1129,"PHASE2":1141,"PHASE3":1143,"PHASE4":1145,"NA":1147},{"trials":1128,"activeCount":76},[],{"trials":1130,"activeCount":76},[1131],{"nctId":1132,"briefTitle":1133,"status":343,"phases":1134,"primaryCompletion":1135,"completion":1136,"start":1137,"enrollment":1138,"conditions":1139,"interventions":1140},"NCT04886050","Relative Bioavailability Study to Assess an LC350189 Tablet Compared to an LC350189 Capsule in Healthy Adults",[65],"2021-09-16","2021-12-10","2021-07-31",23,[15,18],[1125,1125],{"trials":1142,"activeCount":76},[],{"trials":1144,"activeCount":76},[],{"trials":1146,"activeCount":76},[],{"trials":1148,"activeCount":76},[],{"intervention":1150,"totalTrials":72,"cells":1151},"LC28-0126",{"EARLY_PHASE1":1152,"PHASE1":1154,"PHASE2":1165,"PHASE3":1167,"PHASE4":1169,"NA":1171},{"trials":1153,"activeCount":76},[],{"trials":1155,"activeCount":76},[1156],{"nctId":1157,"briefTitle":1158,"status":343,"phases":1159,"primaryCompletion":1160,"completion":1160,"start":1161,"enrollment":1162,"conditions":1163,"interventions":1164},"NCT03196804","A Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of LC28-0126.",[65],"2017-11-15","2017-06-07",32,[30],[1150],{"trials":1166,"activeCount":76},[],{"trials":1168,"activeCount":76},[],{"trials":1170,"activeCount":76},[],{"trials":1172,"activeCount":76},[],{"intervention":649,"totalTrials":72,"cells":1174},{"EARLY_PHASE1":1175,"PHASE1":1177,"PHASE2":1183,"PHASE3":1185,"PHASE4":1187,"NA":1189},{"trials":1176,"activeCount":76},[],{"trials":1178,"activeCount":76},[1179],{"nctId":639,"briefTitle":640,"status":129,"phases":1180,"primaryCompletion":642,"completion":643,"start":644,"enrollment":645,"conditions":1181,"interventions":1182},[65],[647],[649,650,632],{"trials":1184,"activeCount":76},[],{"trials":1186,"activeCount":76},[],{"trials":1188,"activeCount":76},[],{"trials":1190,"activeCount":76},[],{"intervention":650,"totalTrials":72,"cells":1192},{"EARLY_PHASE1":1193,"PHASE1":1195,"PHASE2":1201,"PHASE3":1203,"PHASE4":1205,"NA":1207},{"trials":1194,"activeCount":76},[],{"trials":1196,"activeCount":76},[1197],{"nctId":639,"briefTitle":640,"status":129,"phases":1198,"primaryCompletion":642,"completion":643,"start":644,"enrollment":645,"conditions":1199,"interventions":1200},[65],[647],[649,650,632],{"trials":1202,"activeCount":76},[],{"trials":1204,"activeCount":76},[],{"trials":1206,"activeCount":76},[],{"trials":1208,"activeCount":76},[],{"intervention":352,"totalTrials":72,"cells":1210},{"EARLY_PHASE1":1211,"PHASE1":1213,"PHASE2":1219,"PHASE3":1221,"PHASE4":1223,"NA":1225},{"trials":1212,"activeCount":76},[],{"trials":1214,"activeCount":76},[1215],{"nctId":341,"briefTitle":342,"status":343,"phases":1216,"primaryCompletion":345,"completion":346,"start":347,"enrollment":348,"conditions":1217,"interventions":1218},[65],[350],[352,333,353,354],{"trials":1220,"activeCount":76},[],{"trials":1222,"activeCount":76},[],{"trials":1224,"activeCount":76},[],{"trials":1226,"activeCount":76},[],{"intervention":353,"totalTrials":72,"cells":1228},{"EARLY_PHASE1":1229,"PHASE1":1231,"PHASE2":1237,"PHASE3":1239,"PHASE4":1241,"NA":1243},{"trials":1230,"activeCount":76},[],{"trials":1232,"activeCount":76},[1233],{"nctId":341,"briefTitle":342,"status":343,"phases":1234,"primaryCompletion":345,"completion":346,"start":347,"enrollment":348,"conditions":1235,"interventions":1236},[65],[350],[352,333,353,354],{"trials":1238,"activeCount":76},[],{"trials":1240,"activeCount":76},[],{"trials":1242,"activeCount":76},[],{"trials":1244,"activeCount":76},[],{"intervention":354,"totalTrials":72,"cells":1246},{"EARLY_PHASE1":1247,"PHASE1":1249,"PHASE2":1255,"PHASE3":1257,"PHASE4":1259,"NA":1261},{"trials":1248,"activeCount":76},[],{"trials":1250,"activeCount":76},[1251],{"nctId":341,"briefTitle":342,"status":343,"phases":1252,"primaryCompletion":345,"completion":346,"start":347,"enrollment":348,"conditions":1253,"interventions":1254},[65],[350],[352,333,353,354],{"trials":1256,"activeCount":76},[],{"trials":1258,"activeCount":76},[],{"trials":1260,"activeCount":76},[],{"trials":1262,"activeCount":76},[],{"intervention":1264,"totalTrials":72,"cells":1265},"Gemigliptin",{"EARLY_PHASE1":1266,"PHASE1":1268,"PHASE2":1281,"PHASE3":1283,"PHASE4":1285,"NA":1287},{"trials":1267,"activeCount":76},[],{"trials":1269,"activeCount":76},[1270],{"nctId":1271,"briefTitle":1272,"status":129,"phases":1273,"primaryCompletion":1274,"completion":1275,"start":1276,"enrollment":348,"conditions":1277,"interventions":1278},"NCT03565458","Gemigliptin, Dapagliflozin, Empagliflozin DDI Study",[65],"2018-08-20","2018-12-22","2018-04-05",[350],[1264,1279,1280],"Dapagliflozin","Empagliflozin",{"trials":1282,"activeCount":76},[],{"trials":1284,"activeCount":76},[],{"trials":1286,"activeCount":76},[],{"trials":1288,"activeCount":76},[],{"intervention":1279,"totalTrials":72,"cells":1290},{"EARLY_PHASE1":1291,"PHASE1":1293,"PHASE2":1299,"PHASE3":1301,"PHASE4":1303,"NA":1305},{"trials":1292,"activeCount":76},[],{"trials":1294,"activeCount":76},[1295],{"nctId":1271,"briefTitle":1272,"status":129,"phases":1296,"primaryCompletion":1274,"completion":1275,"start":1276,"enrollment":348,"conditions":1297,"interventions":1298},[65],[350],[1264,1279,1280],{"trials":1300,"activeCount":76},[],{"trials":1302,"activeCount":76},[],{"trials":1304,"activeCount":76},[],{"trials":1306,"activeCount":76},[],{"intervention":1280,"totalTrials":72,"cells":1308},{"EARLY_PHASE1":1309,"PHASE1":1311,"PHASE2":1317,"PHASE3":1319,"PHASE4":1321,"NA":1323},{"trials":1310,"activeCount":76},[],{"trials":1312,"activeCount":76},[1313],{"nctId":1271,"briefTitle":1272,"status":129,"phases":1314,"primaryCompletion":1274,"completion":1275,"start":1276,"enrollment":348,"conditions":1315,"interventions":1316},[65],[350],[1264,1279,1280],{"trials":1318,"activeCount":76},[],{"trials":1320,"activeCount":76},[],{"trials":1322,"activeCount":76},[],{"trials":1324,"activeCount":76},[],{"intervention":1326,"totalTrials":72,"cells":1327},"Valsartan",{"EARLY_PHASE1":1328,"PHASE1":1330,"PHASE2":1342,"PHASE3":1344,"PHASE4":1346,"NA":1348},{"trials":1329,"activeCount":76},[],{"trials":1331,"activeCount":76},[1332],{"nctId":1333,"briefTitle":1334,"status":343,"phases":1335,"primaryCompletion":1336,"completion":1337,"start":1338,"enrollment":185,"conditions":1339,"interventions":1340},"NCT03532854","Evaluating a Pharmacokinetic Drug Interaction Between LGEV1801 and LGEV1802",[65],"2018-08-25","2019-01-30","2018-05-28",[912],[1326,1341],"Ezetimibe\u002FRosuvastatin",{"trials":1343,"activeCount":76},[],{"trials":1345,"activeCount":76},[],{"trials":1347,"activeCount":76},[],{"trials":1349,"activeCount":76},[],{"intervention":1341,"totalTrials":72,"cells":1351},{"EARLY_PHASE1":1352,"PHASE1":1354,"PHASE2":1360,"PHASE3":1362,"PHASE4":1364,"NA":1366},{"trials":1353,"activeCount":76},[],{"trials":1355,"activeCount":76},[1356],{"nctId":1333,"briefTitle":1334,"status":343,"phases":1357,"primaryCompletion":1336,"completion":1337,"start":1338,"enrollment":185,"conditions":1358,"interventions":1359},[65],[912],[1326,1341],{"trials":1361,"activeCount":76},[],{"trials":1363,"activeCount":76},[],{"trials":1365,"activeCount":76},[],{"trials":1367,"activeCount":76},[],{"intervention":1369,"totalTrials":72,"cells":1370},"Monolayer group",{"EARLY_PHASE1":1371,"PHASE1":1373,"PHASE2":1386,"PHASE3":1388,"PHASE4":1390,"NA":1392},{"trials":1372,"activeCount":76},[],{"trials":1374,"activeCount":76},[1375],{"nctId":1376,"briefTitle":1377,"status":129,"phases":1378,"primaryCompletion":1379,"completion":1380,"start":1381,"enrollment":348,"conditions":1382,"interventions":1384},"NCT03867942","BE Study of Bilayer Combination of Gemigliptin\u002FRosuvastatin 50\u002F20mg in Comparison to Monolayer Combination.",[65],"2019-05-24","2019-08-31","2019-03-21",[368,1383],"Dyslipidemias",[1369,1385],"Bilayer group",{"trials":1387,"activeCount":76},[],{"trials":1389,"activeCount":76},[],{"trials":1391,"activeCount":76},[],{"trials":1393,"activeCount":76},[],{"intervention":1385,"totalTrials":72,"cells":1395},{"EARLY_PHASE1":1396,"PHASE1":1398,"PHASE2":1404,"PHASE3":1406,"PHASE4":1408,"NA":1410},{"trials":1397,"activeCount":76},[],{"trials":1399,"activeCount":76},[1400],{"nctId":1376,"briefTitle":1377,"status":129,"phases":1401,"primaryCompletion":1379,"completion":1380,"start":1381,"enrollment":348,"conditions":1402,"interventions":1403},[65],[368,1383],[1369,1385],{"trials":1405,"activeCount":76},[],{"trials":1407,"activeCount":76},[],{"trials":1409,"activeCount":76},[],{"trials":1411,"activeCount":76},[],{"intervention":1413,"totalTrials":72,"cells":1414},"DTP-HepB-IPV-Hib vaccine",{"EARLY_PHASE1":1415,"PHASE1":1417,"PHASE2":1429,"PHASE3":1431,"PHASE4":1433,"NA":1435},{"trials":1416,"activeCount":76},[],{"trials":1418,"activeCount":76},[1419],{"nctId":1420,"briefTitle":1421,"status":343,"phases":1422,"primaryCompletion":1423,"completion":1424,"start":1425,"enrollment":185,"conditions":1426,"interventions":1427},"NCT03208101","A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy Adults",[65],"2017-09-06","2017-12-21","2017-07-03",[22,24,26,20,28,187],[1413,1428],"DTP-HepB-Hib vaccine & IPV",{"trials":1430,"activeCount":76},[],{"trials":1432,"activeCount":76},[],{"trials":1434,"activeCount":76},[],{"trials":1436,"activeCount":76},[],{"intervention":1428,"totalTrials":72,"cells":1438},{"EARLY_PHASE1":1439,"PHASE1":1441,"PHASE2":1447,"PHASE3":1449,"PHASE4":1451,"NA":1453},{"trials":1440,"activeCount":76},[],{"trials":1442,"activeCount":76},[1443],{"nctId":1420,"briefTitle":1421,"status":343,"phases":1444,"primaryCompletion":1423,"completion":1424,"start":1425,"enrollment":185,"conditions":1445,"interventions":1446},[65],[22,24,26,20,28,187],[1413,1428],{"trials":1448,"activeCount":76},[],{"trials":1450,"activeCount":76},[],{"trials":1452,"activeCount":76},[],{"trials":1454,"activeCount":76},[],{"intervention":1456,"totalTrials":72,"cells":1457},"Zemiglo 50mg and Forxiga 10mg",{"EARLY_PHASE1":1458,"PHASE1":1460,"PHASE2":1474,"PHASE3":1476,"PHASE4":1478,"NA":1480},{"trials":1459,"activeCount":76},[],{"trials":1461,"activeCount":76},[1462],{"nctId":1463,"briefTitle":1464,"status":129,"phases":1465,"primaryCompletion":1466,"completion":1467,"start":1468,"enrollment":1469,"conditions":1470,"interventions":1472},"NCT04544319","Clinical Trial to Compare the PK of the Fixed-dose Combinations and Each Component of Gemigliptin\u002FDapagliflozin 50\u002F10 mg",[65],"2021-03","2021-07","2020-10",44,[1471],"T2DM",[1456,1473],"Fixed-dose Combinations of Gemigliptin\u002FDapagliflozin 50\u002F10 mg",{"trials":1475,"activeCount":76},[],{"trials":1477,"activeCount":76},[],{"trials":1479,"activeCount":76},[],{"trials":1481,"activeCount":76},[],{"intervention":1473,"totalTrials":72,"cells":1483},{"EARLY_PHASE1":1484,"PHASE1":1486,"PHASE2":1492,"PHASE3":1494,"PHASE4":1496,"NA":1498},{"trials":1485,"activeCount":76},[],{"trials":1487,"activeCount":76},[1488],{"nctId":1463,"briefTitle":1464,"status":129,"phases":1489,"primaryCompletion":1466,"completion":1467,"start":1468,"enrollment":1469,"conditions":1490,"interventions":1491},[65],[1471],[1456,1473],{"trials":1493,"activeCount":76},[],{"trials":1495,"activeCount":76},[],{"trials":1497,"activeCount":76},[],{"trials":1499,"activeCount":76},[],{"intervention":880,"totalTrials":72,"cells":1501},{"EARLY_PHASE1":1502,"PHASE1":1504,"PHASE2":1510,"PHASE3":1512,"PHASE4":1514,"NA":1516},{"trials":1503,"activeCount":76},[],{"trials":1505,"activeCount":76},[1506],{"nctId":873,"briefTitle":874,"status":343,"phases":1507,"primaryCompletion":876,"completion":876,"start":877,"enrollment":476,"conditions":1508,"interventions":1509},[65],[15,18],[866,880],{"trials":1511,"activeCount":76},[],{"trials":1513,"activeCount":76},[],{"trials":1515,"activeCount":76},[],{"trials":1517,"activeCount":76},[],{"intervention":1519,"totalTrials":72,"cells":1520},"Test Drug",{"EARLY_PHASE1":1521,"PHASE1":1523,"PHASE2":1534,"PHASE3":1536,"PHASE4":1538,"NA":1540},{"trials":1522,"activeCount":76},[],{"trials":1524,"activeCount":76},[1525],{"nctId":1526,"briefTitle":1527,"status":343,"phases":1528,"primaryCompletion":1529,"completion":1529,"start":1530,"enrollment":348,"conditions":1531,"interventions":1532},"NCT06743997","A Study to Compare Eutropin Formulations in Healthy Volunteers for Bioavailability, Safety, and Tolerability",[65],"2025-04-15","2025-01-13",[302],[1519,1533],"Reference Drug",{"trials":1535,"activeCount":76},[],{"trials":1537,"activeCount":76},[],{"trials":1539,"activeCount":76},[],{"trials":1541,"activeCount":76},[],{"intervention":1533,"totalTrials":72,"cells":1543},{"EARLY_PHASE1":1544,"PHASE1":1546,"PHASE2":1552,"PHASE3":1554,"PHASE4":1556,"NA":1558},{"trials":1545,"activeCount":76},[],{"trials":1547,"activeCount":76},[1548],{"nctId":1526,"briefTitle":1527,"status":343,"phases":1549,"primaryCompletion":1529,"completion":1529,"start":1530,"enrollment":348,"conditions":1550,"interventions":1551},[65],[302],[1519,1533],{"trials":1553,"activeCount":76},[],{"trials":1555,"activeCount":76},[],{"trials":1557,"activeCount":76},[],{"trials":1559,"activeCount":76},[],{"intervention":1561,"totalTrials":72,"cells":1562},"[14C] LC350189",{"EARLY_PHASE1":1563,"PHASE1":1565,"PHASE2":1575,"PHASE3":1577,"PHASE4":1579,"NA":1581},{"trials":1564,"activeCount":76},[],{"trials":1566,"activeCount":76},[1567],{"nctId":1568,"briefTitle":1569,"status":343,"phases":1570,"primaryCompletion":1571,"completion":1571,"start":1572,"enrollment":31,"conditions":1573,"interventions":1574},"NCT04070846","Mass Balance Study of [14C]LC350189 in Healthy Volunteers",[65],"2020-03-07","2020-02-26",[15,18],[1561],{"trials":1576,"activeCount":76},[],{"trials":1578,"activeCount":76},[],{"trials":1580,"activeCount":76},[],{"trials":1582,"activeCount":76},[],{"intervention":1584,"totalTrials":72,"cells":1585},"LB64640",{"EARLY_PHASE1":1586,"PHASE1":1588,"PHASE2":1602,"PHASE3":1604,"PHASE4":1606,"NA":1608},{"trials":1587,"activeCount":76},[],{"trials":1589,"activeCount":76},[1590],{"nctId":1591,"briefTitle":1592,"status":343,"phases":1593,"primaryCompletion":1594,"completion":1595,"start":1596,"enrollment":1597,"conditions":1598,"interventions":1601},"NCT06040372","A First in Human Study to Assess the Safety, Tolerability of LB54640 in in Healthy Overweight and Obese Subjects",[65],"2022-03-30","2022-07-30","2020-03-16",112,[1599,1600,30],"Obese","Overweight",[1584],{"trials":1603,"activeCount":76},[],{"trials":1605,"activeCount":76},[],{"trials":1607,"activeCount":76},[],{"trials":1609,"activeCount":76},[],{"intervention":1611,"totalTrials":72,"cells":1612},"Gemigliptin\u002FMetformin Hydrochloride Sustained Release 50\u002F1000 mg",{"EARLY_PHASE1":1613,"PHASE1":1615,"PHASE2":1624,"PHASE3":1626,"PHASE4":1628,"NA":1630},{"trials":1614,"activeCount":76},[],{"trials":1616,"activeCount":76},[1617],{"nctId":1618,"briefTitle":1619,"status":129,"phases":1620,"primaryCompletion":830,"completion":1621,"start":831,"enrollment":476,"conditions":1622,"interventions":1623},"NCT04070794","Food-effect Bioavailability of Fixed Dose Combination Zemimet® SR Tab. 50\u002F1000 mg Under Fed and Fasting Conditions",[65],"2019-12-30",[833],[1611,1611],{"trials":1625,"activeCount":76},[],{"trials":1627,"activeCount":76},[],{"trials":1629,"activeCount":76},[],{"trials":1631,"activeCount":76},[],{"intervention":1633,"totalTrials":72,"cells":1634},"LC350189 200 mg",{"EARLY_PHASE1":1635,"PHASE1":1637,"PHASE2":1648,"PHASE3":1650,"PHASE4":1652,"NA":1654},{"trials":1636,"activeCount":76},[],{"trials":1638,"activeCount":76},[1639],{"nctId":1640,"briefTitle":1641,"status":343,"phases":1642,"primaryCompletion":1643,"completion":1643,"start":1644,"enrollment":1645,"conditions":1646,"interventions":1647},"NCT04066712","Renal PK Study of LC350189",[65],"2020-09-12","2019-11-19",37,[15,18],[1633],{"trials":1649,"activeCount":76},[],{"trials":1651,"activeCount":76},[],{"trials":1653,"activeCount":76},[],{"trials":1655,"activeCount":76},[],{"intervention":1657,"totalTrials":72,"cells":1658},"gemigliptin and dapagliflozin 50\u002F10 mg film-coated",{"EARLY_PHASE1":1659,"PHASE1":1661,"PHASE2":1672,"PHASE3":1674,"PHASE4":1676,"NA":1678},{"trials":1660,"activeCount":76},[],{"trials":1662,"activeCount":76},[1663],{"nctId":1664,"briefTitle":1665,"status":129,"phases":1666,"primaryCompletion":1667,"completion":1668,"start":1669,"enrollment":277,"conditions":1670,"interventions":1671},"NCT05105698","Food-effect Bioavailability of Gemigliptin and Dapagliflozin 50\u002F10 mg",[65],"2022-02-28","2022-09-30","2022-01-01",[302],[1657,1657],{"trials":1673,"activeCount":76},[],{"trials":1675,"activeCount":76},[],{"trials":1677,"activeCount":76},[],{"trials":1679,"activeCount":76},[],{"intervention":1681,"totalTrials":72,"cells":1682},"LC350189 200mg",{"EARLY_PHASE1":1683,"PHASE1":1696,"PHASE2":1698,"PHASE3":1700,"PHASE4":1702,"NA":1704},{"trials":1684,"activeCount":76},[1685],{"nctId":1686,"briefTitle":1687,"status":343,"phases":1688,"primaryCompletion":1689,"completion":1689,"start":1690,"enrollment":1645,"conditions":1691,"interventions":1693},"NCT04966325","Thorough QT (TQT) Study to Evaluate the Effect of LC350189 on Cardiac Repolarization in Healthy Male and Female Subjects",[64],"2021-12-07","2021-09-23",[18,15,1692],"Qt Interval, Variation in",[1681,1694,1695],"Moxifloxacin 400mg","LC350189 600mg",{"trials":1697,"activeCount":76},[],{"trials":1699,"activeCount":76},[],{"trials":1701,"activeCount":76},[],{"trials":1703,"activeCount":76},[],{"trials":1705,"activeCount":76},[],{"intervention":1694,"totalTrials":72,"cells":1707},{"EARLY_PHASE1":1708,"PHASE1":1714,"PHASE2":1716,"PHASE3":1718,"PHASE4":1720,"NA":1722},{"trials":1709,"activeCount":76},[1710],{"nctId":1686,"briefTitle":1687,"status":343,"phases":1711,"primaryCompletion":1689,"completion":1689,"start":1690,"enrollment":1645,"conditions":1712,"interventions":1713},[64],[18,15,1692],[1681,1694,1695],{"trials":1715,"activeCount":76},[],{"trials":1717,"activeCount":76},[],{"trials":1719,"activeCount":76},[],{"trials":1721,"activeCount":76},[],{"trials":1723,"activeCount":76},[],{"intervention":1695,"totalTrials":72,"cells":1725},{"EARLY_PHASE1":1726,"PHASE1":1732,"PHASE2":1734,"PHASE3":1736,"PHASE4":1738,"NA":1740},{"trials":1727,"activeCount":76},[1728],{"nctId":1686,"briefTitle":1687,"status":343,"phases":1729,"primaryCompletion":1689,"completion":1689,"start":1690,"enrollment":1645,"conditions":1730,"interventions":1731},[64],[18,15,1692],[1681,1694,1695],{"trials":1733,"activeCount":76},[],{"trials":1735,"activeCount":76},[],{"trials":1737,"activeCount":76},[],{"trials":1739,"activeCount":76},[],{"trials":1741,"activeCount":76},[],{"intervention":1743,"totalTrials":72,"cells":1744},"Rosuvastatin\u002FValsartan",{"EARLY_PHASE1":1745,"PHASE1":1747,"PHASE2":1749,"PHASE3":1751,"PHASE4":1753,"NA":1755},{"trials":1746,"activeCount":76},[],{"trials":1748,"activeCount":76},[],{"trials":1750,"activeCount":76},[],{"trials":1752,"activeCount":76},[],{"trials":1754,"activeCount":76},[],{"trials":1756,"activeCount":76},[1757],{"nctId":1758,"briefTitle":1759,"status":129,"phases":1760,"primaryCompletion":1761,"completion":1762,"start":1763,"enrollment":1764,"conditions":1765,"interventions":1768},"NCT04398771","To Evaluate Safety and Effectiveness of RovatitanTab.",[],"2022-01-31","2022-05-31","2020-09-01",1000,[1766,1767],"Hypertension","Hyperlipidemias",[1743],{"intervention":1770,"totalTrials":72,"cells":1771},"Synovian®",{"EARLY_PHASE1":1772,"PHASE1":1774,"PHASE2":1776,"PHASE3":1778,"PHASE4":1780,"NA":1782},{"trials":1773,"activeCount":76},[],{"trials":1775,"activeCount":76},[],{"trials":1777,"activeCount":76},[],{"trials":1779,"activeCount":76},[],{"trials":1781,"activeCount":76},[],{"trials":1783,"activeCount":76},[1784],{"nctId":1785,"briefTitle":1786,"status":343,"phases":1787,"primaryCompletion":1788,"completion":1788,"start":1789,"enrollment":1790,"conditions":1791,"interventions":1793},"NCT04369261","Observational Study of Synovian® Inj. in Patients With Osteoarthritis in the Knee",[],"2019-08-08","2018-03-09",1949,[1792],"Osteoarthritis in the Knee",[1770],{"intervention":1795,"totalTrials":72,"cells":1796},"rFSH",{"EARLY_PHASE1":1797,"PHASE1":1799,"PHASE2":1801,"PHASE3":1803,"PHASE4":1805,"NA":1807},{"trials":1798,"activeCount":76},[],{"trials":1800,"activeCount":76},[],{"trials":1802,"activeCount":76},[],{"trials":1804,"activeCount":76},[],{"trials":1806,"activeCount":76},[],{"trials":1808,"activeCount":76},[1809],{"nctId":1810,"briefTitle":1811,"status":343,"phases":1812,"primaryCompletion":1813,"completion":1814,"start":1815,"enrollment":1816,"conditions":1817,"interventions":1819},"NCT05130125","Retrospective Cohort Observational Study to Evaluate the Effectiveness and Safety of Fresh or Frozen Embryo Transfer",[],"2022-12-31","2023-06-30","2021-09-14",1166,[1818],"Infertility, Female",[1795]]